PFM Health Sciences LP Cuts Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

PFM Health Sciences LP cut its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 4.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,000,787 shares of the biotechnology company’s stock after selling 519,444 shares during the period. PFM Health Sciences LP’s holdings in Adaptimmune Therapeutics were worth $9,505,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ADAP. Fullcircle Wealth LLC purchased a new stake in Adaptimmune Therapeutics during the third quarter valued at about $33,000. Vontobel Holding Ltd. raised its stake in shares of Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 30,000 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics during the third quarter valued at about $95,000. FMR LLC raised its stake in shares of Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after acquiring an additional 394,566 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ ADAP opened at $0.72 on Friday. The company has a 50 day simple moving average of $0.81 and a two-hundred day simple moving average of $1.00. Adaptimmune Therapeutics plc has a fifty-two week low of $0.43 and a fifty-two week high of $2.05. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The company has a market capitalization of $184.41 million, a price-to-earnings ratio of -3.28 and a beta of 2.26.

Analyst Ratings Changes

ADAP has been the subject of a number of research reports. StockNews.com downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright decreased their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Mizuho decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Adaptimmune Therapeutics currently has an average rating of “Buy” and an average target price of $2.79.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.